Navigation Links
EpiCept Accelerates Development of Phase I Clinical Study for Cancer

lan. We expect to be in a position to report the results of this important clinical trial later this year."

EPC2407 has shown promising vascular targeting activity with nanomolar potencies of anti-tumor activity in pre-clinical in vitro and in vivo studies. The molecule has been shown to induce tumor cell apoptosis and selectively inhibit growth of proliferating cell lines, including multi-drug resistant cell lines. Murine models of human tumor xenografts demonstrated EPC2407 inhibits growth of established tumors of a number of different cancer types more effectively than the other VDAs tested and was synergistic when used in combination with anticancer agents, such as Cisplatin. The combination of EPC2407 with other anticancer agents in a Phase 1b trial is planned to follow the current monotherapy trial. EPC2407 is one of two VDA compounds currently in clinical trials discovered through EpiCept's Anti-cancer Screening Apoptosis Program (ASAP). The second compound, Azixa(TM), is part of the EP90745 series of apoptosis inducers, which was licensed by EpiCept to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement. Myriad recently announced that Azixa(TM) has a second mode of action due to vascular disruption activity (VDA). The compound is currently being evaluated in two Phase II human clinical trials, one in patients with primary brain cancer and the other in brain metastases due to melanoma. EpiCept's licensing agreement with Myriad for Azixa includes milestone payments, and sublicensing income as well as future royalties in the event Myriad's development of Azixa continues to progress successfully.
'"/>




Page: 1 2

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Missing Protein In Cancer Development
4. Tomatoes Might Inhibit the Development Of Prostate Cancer
5. Pollution Found To Impair Lung Development
6. Treating Depression In Children Could Lead To Poor Bone Development
7. Developmental Origins of Polycystic Ovarian Syndrome
8. Sleep Not Critical For Early Brain Development Of Baby Dolphins
9. ‘Loud Noise’ Research may help in Development of Prosthetics for Eldery
10. Stop Watching TV: Toddler Development Affected
11. Vitamin Supplements During Pregnancy to Boost Fetal Development
Post Your Comments:
(Date:10/15/2008)... Will Educate Parents about Prescription,Drug Abus...mily Partnership (NFP),has designated Monday, Octo...g off the group,s 23rd annual Red Ribbon Week from...ents with action steps to prevent children,s,presc...million teens in the United States abuse,prescript...
(Date:10/14/2008)...4 /PRNewswire-USNewswire/ -- Kerby T.,Alvy, Ph.D.,...r for the,Improvement in North Hollywood (CICC), h... and Prevention (CDC) to serve as an expert to inf...or the prevention of child,maltreatment., CDC,s n...lationships,(SSNR) as the foundation for a unified...
(Date:10/14/2008)...ker Founder and CEO Andrew Levitt to showcase Heal... Somerville, MA (PRWEB) Octob... , the word-of-mouth marketing (WOM) firm for the ... announced that Andrew Levitt, Founder and CEO of ...Pharma and Health 2.0" at Health 2.0: User-Ge...
(Date:10/14/2008)...PRNewswire-FirstCall/ -- Warner Chilcott,Limited (... its third quarter,2008 financial results prior to... In addition to issuing a press release, the Comp... parties on Monday, November 10, 2008 at,8:00 AM (...e in the call,please dial (877) 856-1955 in the U...
Breaking Medicine News(10 mins):Health News:National Family Partnership Designates October 27th 'Lock Your Meds' Day 2Health News:National Family Partnership Designates October 27th 'Lock Your Meds' Day 3Health News:Los Angeles Psychologist to Help CDC Fight Child Abuse 2Health News:HealthTalker Founder and CEO Andrew Levitt to be Featured at 'Health 2.0: User-Generated Healthcare 2008' 2
...econd largest AIDS capital in the United States. T...ics//. However its been found that primary care pr... are often failing to offer either HIV testing or ...a new UCLA AIDS Institute study. Hence AIDS cases ...
...chronic diseases], more people can live longer.'Ra...vent and treat diseases are bringing// closer the ...tential to live 100 years or longer, said Dr. Pasc...ty of Miami Miller School of Medicine. ''In five ...
...wmakers -- including Sens. Debbie Stabenow (D-Mich... Cubin (R-Wyo.) and Lois Capps (D-Calif.) -- earli...1014) that aims to improve heart disease education...d increase women's access to heart disease screeni...
...t study, the ages at which teenagers and children ...e a significant impact on their delinquent behavio... is a case of first intercourse earlier than their...was published in February edition of the Journal o...
Other Medicine News:Health News:Primary Health Care Parishioners of Second Largest HIV Infected Area in US Fail to Offer HIV Tests 2Health News:Primary Health Care Parishioners of Second Largest HIV Infected Area in US Fail to Offer HIV Tests 3Health News:Genetics Might Engineer Path to Successful Aging 2
(Date:10/14/2008)...4 /PRNewswire-USNewswire/ -- Susan G. Komen for th...n unprecedented $100,million in grants to American...ast track breast cancer research. Grants were also... from the Barbara Ann Karmanos Cancer Institute an... Boerner, Ph.D., assistant,professor, and Guojun W...
(Date:10/14/2008)...t. 10 /- Regado Biosciences, Inc.,an... in the Phase IIa,clinical study of its REG1 Antic...percutaneous coronary intervention (PCI). REG1 is ...d anticoagulant, RB006, and its matched,active re...nd neutralizes,RB006. The Phase IIa study (REVERSA...
(Date:10/13/2008)... million dollar NIH funding advances study S... rates, MINNEAPOLIS, Oct. 13 /- Adva...edcirculatory.com ) announced today that it has re...the National Institutes of,Health (NIH) to continu...on,those who experience cardiac arrest outside a h...
(Date:10/13/2008)...nnounce Interim Results in January 2009 and Final ..., EMERYVILLE, Calif., Oct. 13 /PRNewswire-FirstCa... (Nasdaq: NTII ) today announced that following a...n to discuss the,Viprinex(TM) (ancrod) Phase 3 cli...ny plans to consolidate and analyze data from its ...
Breaking Medicine Technology:Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants 2Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants 3Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants 4Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants 5Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System 2Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System 3Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 2Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 3Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 4Before Every Surgery Take a TIME OUT 28R 29 5745 1Before Every Surgery Take a TIME OUT 28R 29 5745 2Black Athletes Hearts May Differ From Those of Whites 20899 1Black Athletes Hearts May Differ From Those of Whites 20899 2Black Athletes Hearts May Differ From Those of Whites 20899 3Katzen Eye Group Announces a New Option in Vision Correction Technology for Patients 20895 1Katzen Eye Group Announces a New Option in Vision Correction Technology for Patients 20895 2Olympic Champion Mary Lou Retton and ASCO Join Frosted Pink with a Twist to Empower Women Through Education and Advocacy 20891 1Olympic Champion Mary Lou Retton and ASCO Join Frosted Pink with a Twist to Empower Women Through Education and Advocacy 20891 2Olympic Champion Mary Lou Retton and ASCO Join Frosted Pink with a Twist to Empower Women Through Education and Advocacy 20891 3Olympic Champion Mary Lou Retton and ASCO Join Frosted Pink with a Twist to Empower Women Through Education and Advocacy 20891 4
The Blackstone Spinal Fixation System is a sophisticated fixation system that provides an innovative solution to spinal stabilization. It combines technical advances in strength and stability with a
...is a versatile, low profile, titanium implant comp...trumentation needed for implantation. Reduction in...g concept. Monosegmental and multisegmental applic... with over 8,000 implantations. Tested in accordan...
...em is a comprehensive and versatile hook, rod and ...nd degenerative cases. Conceived with a complete u...LA/VSP Spine System employs segmental fixation and...bilize the spine. In deformity cases, the ISOLA/VS...
Transcranial and peripheral vascular doppler system.
Medicine Products: